{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:02:59Z","timestamp":1772146979589,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajog.2025.06.048","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:36:55Z","timestamp":1750851415000},"page":"621.e1-621.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Co-administration of combined oral contraceptives and psychotropic drugs: risk of contraceptive failure and adverse events"],"prefix":"10.1016","volume":"233","author":[{"given":"Tanja","family":"Boehnke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaas","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Koelkebeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Kolberg-Liedtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2025.06.048_bib1","first-page":"1","article-title":"U S. Medical eligibility criteria for contraceptive use, 2010","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajog.2025.06.048_bib2","first-page":"1","article-title":"U.S. Selected practice recommendations for contraceptive use, 2013","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajog.2025.06.048_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.contraception.2016.07.017","article-title":"Research gaps from evidence-based contraception guidance: the US medical eligibility criteria for contraceptive use, 2016, and the US selected practice recommendations for contraceptive use, 2016","volume":"94","author":"Horton","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.contraception.2016.07.010","article-title":"Co-administration of St. John's wort and hormonal contraceptives: a systematic review","volume":"94","author":"Berry-Bibee","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.contraception.2016.07.011","article-title":"Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review","volume":"94","author":"Berry-Bibee","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17425255.2022.2106214","article-title":"Drug-drug interactions between psychotropic medications and oral contraceptives","volume":"18","author":"Schoretsanitis","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ajog.2025.06.048_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2024.110375","article-title":"Systematic analysis of combined oral contraceptive prescription patterns in psychotropic drug users across twelve European countries","volume":"132","author":"Boehnke","year":"2024","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40596-017-0806-1","article-title":"Residents perceive limited education on family planning and contraception for patients with severe and persistent mental illness","volume":"42","author":"Macaluso","year":"2018","journal-title":"Acad Psychiatry"},{"key":"10.1016\/j.ajog.2025.06.048_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17\u03b2-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.ajog.2025.06.048_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2288-9-77","article-title":"International Active Surveillance study of women taking Oral Contraceptives (INAS-OC study)","volume":"9","author":"Dinger","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ajog.2025.06.048_bib15","series-title":"Real world health care data analysis: causal methods and implementation using SAS","author":"Faries","year":"2020"},{"key":"10.1016\/j.ajog.2025.06.048_bib16","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.ajog.2025.06.048_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2023.109953","article-title":"Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes","volume":"120","author":"Sarayani","year":"2023","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40261-013-0117-6","article-title":"Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant","volume":"33","author":"Chen","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ajog.2025.06.048_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1067\/mob.2002.124939","article-title":"Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy","volume":"187","author":"Koke","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.ajog.2025.06.048_bib20","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1046\/j.1365-2125.2000.00153.x","article-title":"Ziprasidone and the pharmacokinetics of a combined oral contraceptive","volume":"49","author":"Muirhead","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2025.06.048_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.seizure.2019.11.011","article-title":"Bidirectional interaction between oral contraception and lamotrigine in women with epilepsy - role of progestins","volume":"74","author":"Rauchenzauner","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.ajog.2025.06.048_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cts.12499","article-title":"Role of CYP3A in oral contraceptives clearance","volume":"11","author":"Zhang","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ajog.2025.06.048_bib23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/cpt.2690","article-title":"Development of a translational exposure-bracketing approach to streamline the development of hormonal contraceptive drug products","volume":"112","author":"Cicali","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ajog.2025.06.048_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2020.12.002","article-title":"Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system","volume":"103","author":"Sunaga","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/cpt.1848","article-title":"The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam","volume":"108","author":"Wiesinger","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ajog.2025.06.048_bib26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/dmd.122.000854","article-title":"Combined oral contraceptives as victims of drug interactions","volume":"51","author":"Li","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajog.2025.06.048_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2024.110786","article-title":"Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: a pooled analysis of real-world data","volume":"144","author":"Boehnke","year":"2025","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2025.06.048_bib28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/EDE.0000000000001302","article-title":"A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives in the presence of drug-drug interactions","volume":"32","author":"Sarayani","year":"2021","journal-title":"Epidemiology"},{"key":"10.1016\/j.ajog.2025.06.048_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cpt.277","article-title":"Pharmacoepidemiologic methods for studying the health effects of drug-drug interactions","volume":"99","author":"Hennessy","year":"2016","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825004260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825004260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:41:26Z","timestamp":1768873286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937825004260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0002937825004260"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2025.06.048","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-administration of combined oral contraceptives and psychotropic drugs: risk of contraceptive failure and adverse events","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2025.06.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}